Breast cancer patients preferences for oral versus intravenous second-line anticancer therapy

Wojtacki, Janusz; Wiraszka,; Rolka-Stempniewicz, G.; Grzegorczyk, Magdalena

doi:10.1016/s1359-6349(06)80401-5

Cited by 18 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral therapy represents a major change in contemporary oncology practice since it has unquestionable advantages in terms of pharmacoeconomic issues, patient convenience and potentially improved quality of life over intravenous one. Moreover, several studies have shown that patients with various types of neoplasms prefer oral anticancer chemotherapy rather intravenous one if efficacy of oral agents is warranted [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Gebbia

Bellavia

Ferraú

et al. 2011

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Gebbia

Bellavia

Ferraú

et al. 2011

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

show abstract

“…[5][6][7] Nevertheless, a minority of patients prefer intravenous therapy because they believe that oral therapy is less effective than intravenous treatment. [7][8][9] We aimed to report the efficacy and toxicity of capecitabine and oral cyclophosphamide combination in anthracyclin and taxane resistant MBC patients.…”

Section: Introductionmentioning

confidence: 99%

Capecitabine and Oral Cyclophosphamide Combination in Taxane/Antrhracycline Resistant Metastatic Breast Cancer

Özet¹

2011

UHOD

View full text Add to dashboard Cite

No combination chemotherapy has been shown yet to be more effective in metastatic breast cancer (MBC) patients who did not either respond to taxanes and anthracyclines or recurred thereafter. We aimed to report in short term the effect and toxicity results of capecitabine and oral cyclophosphamide combination in MBC patients with anthracyclin and taxane resistance. Between January and September 2007, totally 11 patients were enrolled. All of them had received anthracyclines and taxanes previously either in metastatic or adjuvant setting. They were given capecitabine (1000 mg/m 2 bid) and oral cychlophosphamide (30 mg/m 2 tid) on days 1 to 14 every 3 weeks.Median age of patients was 48 years. The median number of previous chemotherapy lines given was 3. Seven patients had received trastuzumab previously, either as monotherapy or as part of combination chemotherapy. Seven had received capecitabine monotherapy before. Median follow-up was 5 months. The patients received a median of 8 cycles chemotherapy. In 4 patients (36.4%) partial response was obtained. Five patients (45.5%) remained stable, and 2 (18.1%) progressed. Median duration of response was 5 months. At the analysis time, 2 patients were dead. Totally 2 patients (18.1%) had grade 2 leucopenia, 2 (18.1%) had grade 2 hand-foot syndrome, 1 (9.1%) had grade 3 hand-foot syndrome. Capecitabine and oral cyclophosphamide combination is a promising and well tolerated regimen in patients who previously had received taxanes and anthracyclines and in patients with cerbB2 positive tumors who received trastuzumab previously. Keywords: Breast neoplasms, Cyclophosphamide, Capecitabine ÖZET Antrasiklin ve Taksan Rezistan Metastatik Meme Kanserli Hastalarda Kapesitabin ve Oral Siklofosfamid KombinasyonuTaksan ve antrasiklinlere yan›t vermeyen veya bu tedaviler sonras›nda tekrarlayan metastatik meme kanserli hastalarda daha etkili oldu¤u gösterilen bir kombinasyon kemoterapisi bulunmamaktad›r. Taksan ve antrasiklin rezistan metastatik meme kanserli hastalarda kapesitabin ve oral siklofosfamid kombinasyonunun k›sa dönemde etkinli¤i ve toksisitesini bildirmeyi amaçlad›k. Ocak ve Eylül 2007 tarihleri aras›nda toplam 11 hasta çal›flmaya al›nd›. Hastalar›n hepsi ya adjuvant ya da metastatik dönem-de taksan ve antrasiklin tedavisi alm›fllard›. Hastalara 3 haftada bir 1-14 günler aras›nda kapesitabin (1000 mg/m 2 günde 2 defa) ve oral siklofosfamid (30 mg/m 2 günde 3 defa) verildi. ULUSLARARASı HEMATOLOJI-ONKOLOJI DERGISI ARTICLE

show abstract

“…This places a major burden on patients [15], which can be reduced with homebased therapy. This benefit may be particularly important for patients living in remote areas or far from an oncology clinic [4]. In the past, healthcare professionals may have believed they could best interpret therapeutic choices for their patients [16,17], with a tendency to focus purely on medical requirements without taking into account the impact intravenous therapy may have on patients (e.g.…”

mentioning

confidence: 99%

“…In the past, healthcare professionals may have believed they could best interpret therapeutic choices for their patients [16,17], with a tendency to focus purely on medical requirements without taking into account the impact intravenous therapy may have on patients (e.g. convenience, impact on daily activities and time spent in or travelling to hospital).Lastly, oral chemotherapy may reduce anxiety in patients who are afraid of injections or are worried about a risk of intravenously transmitted diseases [4,5], and may be a more appropriate route of administration if venous access is problematic.Availability of active oral drugs will not ensure their use. Patients need effective, patient-focused education about their therapy, such as written take-home information, diaries, guidelines for dose reduction in case of adverse events and side-effect support kits [18,19].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Effective oral chemotherapy for breast cancer: pillars of strength

2008

View full text Add to dashboard Cite

Traditionally, anticancer therapy has been dominated by intravenous drug therapy. However, oral agents provide an attractive approach to chemotherapy and use of oral treatments is increasing. We discuss the benefits and challenges of oral chemotherapy from the perspectives of patients, healthcare providers and healthcare funders. Important issues include patient preference, efficacy, compliance, bioavailability, reimbursement, use in special patient populations, financial and staff time savings and flexibility of dosing. We review data for traditional oral agents (e.g. cyclophosphamide, methotrexate), newer oral chemotherapies (e.g. capecitabine), oral formulations of traditionally intravenous agents (e.g. vinorelbine, idarubicin) and new biologic agents under evaluation in breast cancer (e.g. tyrosine kinase inhibitors). Lastly, we review studies of all-oral combination regimens. The wealth of data available and the increasing use of oral agents in breast cancer suggest that many of the concerns and perceptions about oral therapy, including efficacy and bioavailability, have been overcome, and that oral therapy will play a major role in breast cancer management in the future in both the metastatic and adjuvant settings. Key words: breast cancer, capecitabine, oral chemotherapy, vinorelbine introduction Cancer treatment has traditionally been dominated by intravenous drug therapy [1]. There has, however, been a steady increase in the number of oral anticancer agents available during recent years, offering obvious benefits in terms of convenience and ease of administration, as well as addressing patients' preference for oral therapy [2][3][4][5]. It is estimated that one-quarter of all anticancer agents under development are oral agents [6]. Several agents that are already approved in a range of tumour types (e.g. capecitabine, erlotinib, gefitinib, imatinib, lapatinib, lenalidomide, thalidomide, sunitinib, sorafenib) and many others in development (e.g. vatalanib, satraplatin) are or will be available only as oral formulations. Novel approaches to drug delivery, such as the development of hydrophilic polymer carriers to deliver drugs to the gut [7], are likely to further increase the number of oral drugs available.This review investigates the impact of the expanding range of oral agents on cancer treatment, focusing on issues that have previously prevented the use of oral agents in patients with cancer and the opportunities that oral therapy offers. Oral agents that are already available, or that are under clinical evaluation for the treatment of breast cancer, are profiled to illustrate the potential of oral chemotherapy in this patient group.defining the ideal oral agent the patient's perspective Several surveys have shown that most patients prefer oral to intravenous therapy [3,4,8]. Nevertheless, a minority of patients prefer intravenous therapy because they believe that oral therapy is less effective than intravenous treatment [5,8,9]. In a survey of 59 patients starting oral chemotherapy for advanced breas...

show abstract

Breast cancer patients preferences for oral versus intravenous second-line anticancer therapy

Cited by 18 publications

References 0 publications

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

Capecitabine and Oral Cyclophosphamide Combination in Taxane/Antrhracycline Resistant Metastatic Breast Cancer

Effective oral chemotherapy for breast cancer: pillars of strength

Contact Info

Product

Resources

About